Learnings from Real World Evidence of Faricimab in nAMD and DME: Part 2
Arshad M. Khanani, MD, MA, FASRS, highlights the fluid resolution with faricimab and the need for loading doses, especially in high-needs switch patients with nAMD or DME.
Learnings from Real World Evidence of Faricimab in nAMD and DME: Part 1
Arshad M. Khanani, MD, MA, FASRS, discusses rapid improvement with faricimab in several anatomic parameters in treatment-naïve and previously treated patients with nAMD and DME in the TRUCKEE and TAHOE studies.
OPT-302 VEGF-C/D “trap” molecule for AMD promising in Phase 2b, moves to Phase 3
OPT-302 in combination with standard-of-care anti-VEGF-A agents shown to improve visual acuity, anatomic endpoints.
2 Commerce Drive Cranbury, NJ 08512